Aerosol delivery in interstitial lung diseases - breakthrough or lost cause?

Carsten Ehrhardt
DOI: https://doi.org/10.1080/17425247.2024.2348659
2024-05-01
Expert Opinion on Drug Delivery
Abstract:KEYWORDS: Interstitial lung diseases (ILDs) encompass a heterogeneous group of lung disorders, each with its own etiology, clinical presentation, and progression, characterized by inflammation and fibrosis, affecting over 4.5 million people worldwide () [ Citation 1 , Citation 2 ]. ILDs can be idiopathic (i.e. of unknown cause) or secondary to other conditions such as connective tissue diseases, environmental exposures or medication use. A hallmark feature of many ILDs is the progressive fibrosis of the interstitium surrounding the alveoli, resulting in impaired oxygen exchange and a range of debilitating symptoms. ILDs can be challenging to diagnose and manage due to their heterogeneity, with over 200 distinct types having been identified to date [ Citation 1 ]. Most ILDs have a poor prognosis, with a life expectancy of around 3–5 years after diagnosis [ Citation 3 ]. Pulmonary arterial hypertension (PAH) is a significant risk factor and patients with untreated PAH usually rapidly succumb to respiratory failure within 2–3 years after diagnosis [ Citation 3 ].
pharmacology & pharmacy
What problem does this paper attempt to address?